Bausch + Lomb Corp's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 74/208 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 17.15.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Bausch + Lomb Corp's Score
Industry at a Glance
Industry Ranking
74 / 208
Overall Ranking
175 / 4582
Industry
Healthcare Equipment & Supplies
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
14
analysts
Hold
Current Rating
17.154
Target Price
+3.59%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Bausch + Lomb Corp Highlights
StrengthsRisks
Bausch + Lomb Corporation is an eye health company. It operates through three segments: Vision Care, Pharmaceuticals, and Surgical. Vision Care segment includes both a contact lens and a consumer eye care business that consists of contact lens care products, over-the-counter eye drops and eye vitamins. Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices for cataract surgery. Its brands consist of PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, ScoutPro, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, INFUSE, and many more.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 27.15% year-on-year.
Fairly Valued
The company’s latest PE is -19.69, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 42.63M shares, increasing 0.03% quarter-over-quarter.
Bausch + Lomb Corporation is an eye health company. It operates through three segments: Vision Care, Pharmaceuticals, and Surgical. Vision Care segment includes both a contact lens and a consumer eye care business that consists of contact lens care products, over-the-counter eye drops and eye vitamins. Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices for cataract surgery. Its brands consist of PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, ScoutPro, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, INFUSE, and many more.
Ticker SymbolBLCO
CompanyBausch + Lomb Corp
CEOSaunders (Brenton L)
Websitehttps://ir.bausch.com/
FAQs
What is the current price of Bausch + Lomb Corp (BLCO)?
The current price of Bausch + Lomb Corp (BLCO) is 16.950.
What is the symbol of Bausch + Lomb Corp?
The ticker symbol of Bausch + Lomb Corp is BLCO.
What is the 52-week high of Bausch + Lomb Corp?
The 52-week high of Bausch + Lomb Corp is 18.553.
What is the 52-week low of Bausch + Lomb Corp?
The 52-week low of Bausch + Lomb Corp is 10.450.
What is the market capitalization of Bausch + Lomb Corp?
The market capitalization of Bausch + Lomb Corp is 6.00B.
What is the net income of Bausch + Lomb Corp?
The net income of Bausch + Lomb Corp is -317.00M.
Is Bausch + Lomb Corp (BLCO) currently rated as Buy, Hold, or Sell?
According to analysts, Bausch + Lomb Corp (BLCO) has an overall rating of Hold, with a price target of 17.154.
What is the Earnings Per Share (EPS TTM) of Bausch + Lomb Corp (BLCO)?
The Earnings Per Share (EPS TTM) of Bausch + Lomb Corp (BLCO) is -0.862.